Finasteride Tablet, Film Coated
Product Images NDC 50090-7086

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 50090-7086). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Finasteride-fig.1 (Finasteride Fig.1)

A line graph comparing mean change from baseline over four years between Finasteride and placebo groups. The y-axis shows mean change with standard error, and the x-axis marks baseline and annual intervals up to year 4. Data points show Finasteride results consistently below placebo, indicating greater change over time.*

FDA Label Image

Finasteride-fig.2 (Finasteride Fig.2)

A line graph comparing percent of patients over 48 months between Finasteride and placebo groups. The vertical axis shows percent of patients (0% to 15%) and the horizontal axis indicates observation time in months (0 to 48). Finasteride has a lower cumulative percent than placebo. Below the graph are tables displaying cumulative number of events and number of patients at risk per year for placebo and Finasteride groups.*

FDA Label Image

Finasteride-fig.5 (Finasteride Fig.5)

A line graph depicting the percent of subjects with an event over approximately 5.5 years from randomization, comparing four groups: Placebo, Finasteride, Doxazosin, and Combination therapy. The y-axis represents the percent with event, and the x-axis shows years from randomization, illustrating differences in event rates among treatment groups over time.*

FDA Label Image

Structutre (Finasteride Structure)

Chemical structure diagram of finasteride, showing its steroidal backbone with associated functional groups including a keto group and a tert-butyl amide substituent.*

FDA Label Image

Finasteride-fig.3 (Finasteride Fig.3)

A line graph comparing the cumulative percentage of patients over time (up to 48 months) between a Finasteride group and a placebo group. The y-axis shows percent of patients (0% to 15%), and the x-axis shows observation time in months. Below the graph, tables list cumulative numbers of events and patients at risk per year for both groups.*

FDA Label Image

Finasteride-fig4a (Finasteride Fig4a)

Line chart showing mean percent change from baseline with standard error bars over 4 years for placebo and finasteride groups. The x-axis represents time points from baseline to year 4. The y-axis shows percent change from -20 to +20. Placebo group data decreases to about -20% and remains stable, while finasteride group data increases steadily to approximately +15%.*

FDA Label Image

Label Image (Lbl500907086)

Finasteride 5 mg film-coated tablets in a blister pack from A-S Medication Solutions. The label shows NDC 50090-7086-0, specifying 90 tablets per package. Storage instructions advise keeping the product at 68 to 77 degrees Fahrenheit, protected from light. The label includes dosage guidance to see the package insert.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.